AP257A - A method of releasing an antigen from an antibody and methods for their use in diagnosis and therapy. - Google Patents

A method of releasing an antigen from an antibody and methods for their use in diagnosis and therapy. Download PDF

Info

Publication number
AP257A
AP257A APAP/P/1992/000376A AP9200376A AP257A AP 257 A AP257 A AP 257A AP 9200376 A AP9200376 A AP 9200376A AP 257 A AP257 A AP 257A
Authority
AP
ARIPO
Prior art keywords
antibody
antigen
enzyme
binding
bound
Prior art date
Application number
APAP/P/1992/000376A
Other languages
English (en)
Other versions
AP9200376A0 (en
Inventor
Beverley Jane Randle
Original Assignee
Surface Active Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919108954A external-priority patent/GB9108954D0/en
Priority claimed from GB929207192A external-priority patent/GB9207192D0/en
Application filed by Surface Active Ltd filed Critical Surface Active Ltd
Publication of AP9200376A0 publication Critical patent/AP9200376A0/xx
Application granted granted Critical
Publication of AP257A publication Critical patent/AP257A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/972—Modified antibody, e.g. hybrid, bifunctional
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/819—Multifunctional antigen or antibody

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
APAP/P/1992/000376A 1991-04-26 1992-04-24 A method of releasing an antigen from an antibody and methods for their use in diagnosis and therapy. AP257A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919108954A GB9108954D0 (en) 1991-04-26 1991-04-26 Immunoassay method and antibodies for use in such methods
GB929207192A GB9207192D0 (en) 1992-04-01 1992-04-01 Antibodies

Publications (2)

Publication Number Publication Date
AP9200376A0 AP9200376A0 (en) 1992-04-30
AP257A true AP257A (en) 1993-06-03

Family

ID=26298788

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1992/000376A AP257A (en) 1991-04-26 1992-04-24 A method of releasing an antigen from an antibody and methods for their use in diagnosis and therapy.

Country Status (17)

Country Link
US (2) US5573920A (de)
EP (2) EP0511011B1 (de)
JP (1) JP3431140B2 (de)
CN (1) CN1047666C (de)
AP (1) AP257A (de)
AT (1) ATE144624T1 (de)
AU (1) AU665758B2 (de)
CA (1) CA2108451A1 (de)
DE (1) DE69214709T2 (de)
DK (1) DK0511011T3 (de)
ES (1) ES2093778T3 (de)
GR (1) GR3022065T3 (de)
HU (1) HUT66753A (de)
IE (1) IE921342A1 (de)
IL (1) IL101690A (de)
NZ (1) NZ242510A (de)
WO (1) WO1992019973A1 (de)

Families Citing this family (302)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316369D0 (en) * 1993-08-06 1993-09-22 Surface Active Ltd Diagnostic method
GB9421468D0 (en) * 1994-10-18 1994-12-07 Surface Active Ltd Biosensor
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
FR2736642B1 (fr) * 1995-07-10 1997-09-12 Pasteur Institut Immunovecteurs, notamment anticorps et fragments d'anticorps utilisables pour le transport intracellulaire et intranucleaire de principes biologiquement actifs notamment d'haptenes, de proteines et d'acides nucleiques
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
FI100276B (fi) * 1996-02-06 1997-10-31 Orion Yhtymae Oy Menetelmä analyyttien ei-kilpailevaa määritystä varten
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) * 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US20060166276A1 (en) * 1997-09-05 2006-07-27 Lung Health Diagnostics Pty Ltd Method of diagnosis and agents useful for same
DE69841804D1 (de) * 1997-09-05 2010-09-16 Southern Medical Diagnostics P Diagnoseverfahren
AU757694B2 (en) * 1997-09-05 2003-03-06 Southern Medical Diagnostics Pty Ltd A method of diagnosis
WO1999042077A2 (en) * 1998-02-19 1999-08-26 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
DE69943022D1 (de) 1998-03-19 2011-01-20 Human Genome Sciences Rockville Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
US6171802B1 (en) * 1998-06-10 2001-01-09 Kent State University Detection and amplification of ligands
US7052872B1 (en) 1999-06-22 2006-05-30 Immunomedics, Inc. Bi-specific antibodies for pre-targeting diagnosis and therapy
CA2335364C (en) * 1998-06-22 2010-05-04 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7833528B2 (en) 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7387772B1 (en) 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
JP3395673B2 (ja) * 1998-11-18 2003-04-14 株式会社豊田中央研究所 微小酸素電極を利用した特異的結合対測定方法
GB2345133A (en) * 1998-12-24 2000-06-28 Hypoguard Limited Polyspecific antibody immunodiagnostic device
EP1161451A4 (de) 1999-02-26 2006-05-17 Human Genome Sciences Inc Menschliches alpha-endokin und verfahren zu seiner verwendung
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040001826A1 (en) * 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
EP1803730A1 (de) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albuminfusionsproteine
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
EP1294949A4 (de) 2000-06-15 2004-08-25 Human Genome Sciences Inc Menschlicher tumornekrosefaktor delta und epsilon
KR20120053525A (ko) 2000-06-16 2012-05-25 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
AU1994402A (en) 2000-11-28 2002-06-11 Mediummune Inc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
AU2002248184C1 (en) 2000-12-12 2018-01-04 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
EP1683865A3 (de) 2001-02-02 2006-10-25 Eli Lilly & Company Säugerproteine und insbesondere CD200
CN1564826A (zh) 2001-02-09 2005-01-12 人类基因组科学公司 人类g蛋白趋化因子受体(ccr5)hdgnr10
WO2002069904A2 (en) * 2001-03-02 2002-09-12 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
EP1385864B1 (de) 2001-04-13 2010-06-09 Human Genome Sciences, Inc. Anti-VEGF-2 Antikörper
US6867189B2 (en) * 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
EP1997829A1 (de) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin Fusionsproteine
ATE427363T1 (de) 2002-01-08 2009-04-15 Novartis Vaccines & Diagnostic In kanzerísen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
JP2005523688A (ja) * 2002-01-18 2005-08-11 ブリストル−マイヤーズ　スクイブ　カンパニー タンパク質チロシンキナーゼおよび／またはタンパク質チロシンキナーゼ経路と相互作用する化合物の活性を予測するためのポリヌクレオチドおよびポリペプチドの同定
WO2003075957A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
AU2003226065B2 (en) 2002-04-12 2009-02-26 Ludwig Institute For Cancer Research, Ltd Recombinant anti-interleukin-9 antibodies
CN100418981C (zh) * 2002-06-10 2008-09-17 瓦西尼斯公司 在乳腺癌和膀胱癌中差异表达的基因及编码多肽
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
AU2003262650B2 (en) 2002-08-14 2009-10-29 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
ES2641525T3 (es) 2002-10-16 2017-11-10 Purdue Pharma L.P. Anticuerpos que se unen a CA 125/0722P asociado a células y métodos de uso de los mismos
SE0203591D0 (sv) 2002-12-04 2002-12-04 Siemens Elema Ab Förfarande för beredning av ett mediakament och en medicinsk anordning
EP2368578A1 (de) 2003-01-09 2011-09-28 Macrogenics, Inc. Identifizierung und Herstellung von Antikörpern mit abweichenden FC-Regionen und Anwendungsverfahren dafür
AU2004206250B8 (en) * 2003-01-21 2009-09-17 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
EP2289559B1 (de) 2003-02-20 2014-02-12 Seattle Genetics, Inc. Anti-CD70-Antikörper-Arzneimittelkonjugate und deren Verwendung zur Behandlung von Krebs und Immunerkrankungen
WO2004091510A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
WO2005009217A2 (en) * 2003-07-21 2005-02-03 Medimmune, Inc. Diagnosis of pre-cancerous conditions using pcdgf agents
US20050158323A1 (en) * 2003-12-04 2005-07-21 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
US7371381B2 (en) * 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
PT2805728T (pt) 2003-12-23 2020-04-08 Genentech Inc Novos anticorpos anti-il13 e o uso dos mesmos
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
CN100376599C (zh) * 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
EP3073267A1 (de) 2004-09-21 2016-09-28 Medimmune, Inc. Antikörper gegen und verfahren zur herstellung von impfstoffen für respiratorische synzytialvirus
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
WO2006073921A2 (en) * 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function
CN105535967B (zh) 2005-02-15 2022-05-03 杜克大学 抗cd19抗体及其在肿瘤学中的应用
US20060228367A1 (en) * 2005-04-08 2006-10-12 Medimmune, Inc. Antibodies against mammalian metapneumovirus
EP1885755A4 (de) 2005-05-05 2009-07-29 Univ Duke Cd19-antikörper-therapie für autoimmunerkrankungen
JP5065253B2 (ja) 2005-05-06 2012-10-31 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１モノクローナル抗体とその使用法
TWI320788B (en) 2005-05-25 2010-02-21 Hoffmann La Roche Method for the purification of antibodies
AU2006261920A1 (en) 2005-06-23 2007-01-04 Medimmune, Llc Antibody formulations having optimized aggregation and fragmentation profiles
MX2008000253A (es) 2005-07-08 2008-04-02 Biogen Idec Inc Anticuerpos de sp35 y usos de los mismos.
WO2007008604A2 (en) * 2005-07-08 2007-01-18 Bristol-Myers Squibb Company Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
JP2009502180A (ja) 2005-08-03 2009-01-29 アデレイド リサーチ アンド イノベーション ピーティーワイ リミテッド 多糖シンターゼ
SI2573114T1 (sl) 2005-08-10 2016-08-31 Macrogenics, Inc. Identifikacija in inženiring protiteles z variantnimi fc regijami in postopki za njih uporabo
US20070202512A1 (en) * 2005-08-19 2007-08-30 Bristol-Myers Squibb Company Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
ES2551202T5 (es) 2005-11-04 2018-11-30 Genentech, Inc. Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
CA2628238A1 (en) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
US20070136826A1 (en) * 2005-12-02 2007-06-14 Biogen Idec Inc. Anti-mouse CD20 antibodies and uses thereof
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
WO2007103469A2 (en) 2006-03-06 2007-09-13 Aeres Biomedical Ltd. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US7572625B2 (en) * 2006-05-18 2009-08-11 Boston Scientific Scimed, Inc. Medical devices coated with drug carrier macromolecules
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
CA2655080A1 (en) 2006-06-14 2007-12-21 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
AU2007261247A1 (en) * 2006-06-22 2007-12-27 Vaccinex, Inc. Anti-C35 antibodies for treating cancer
LT2029173T (lt) 2006-06-26 2016-11-10 Macrogenics, Inc. Fc riib specifiniai antikūnai ir jų panaudojimo būdai
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
CN103044550A (zh) 2006-09-01 2013-04-17 津莫吉尼蒂克斯公司 Il-31单克隆抗体的可变区序列和使用方法
EP2354254A1 (de) 2006-09-06 2011-08-10 Ortho-McNeil Pharmaceutical, Inc. Biomarker zur Überprüfung der Reaktion auf eine C-Met-Behandlung
WO2008048545A2 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
EP2099823B2 (de) 2006-12-01 2022-02-09 Seagen Inc. Verschiedene zielmoleküle bindende mittel und ihre verwendung
CL2007003661A1 (es) 2006-12-18 2008-07-18 Genentech Inc Regiones de cadena pesada variable y liviana variable; acidos nucleicos que las codifican; metodo de produccion; anticuerpos anti-notch3 que las comprenden; y uso de los anticuerpos para tratar enfermedades relacionadas con el receptor notch3.
US8143071B2 (en) * 2006-12-21 2012-03-27 Phynexus, Inc. Method and device for extracting an analyte
PT2740744T (pt) 2007-01-09 2018-06-06 Biogen Ma Inc Anticorpos sp35 e suas utilizações
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
US7807168B2 (en) * 2007-04-10 2010-10-05 Vaccinex, Inc. Selection of human TNFα specific antibodies
GB0707870D0 (en) 2007-04-23 2007-05-30 Selected Antibodies Ltd Assay Devices and Methods and Components for use Therein
EP2737907A3 (de) 2007-05-07 2014-11-05 MedImmune, LLC Anti-Icos-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
CA2685222C (en) 2007-05-14 2017-12-19 Medimmune, Llc Methods of reducing eosinophil levels
EP2014680A1 (de) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Rekombinante, einkettige, trivalente trispezifische oder bispezifische Antikörperderivate
US20090028857A1 (en) * 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
JP5490714B2 (ja) * 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
EP3561494B1 (de) 2007-12-06 2022-03-02 Genalyte, Inc. VERFAHREN ZUM IDENTIFIZIEREN EINER SEQUENZ VON NUKLEOTIDEN IN EINER UNBEKANNTEN SPEZIES VON NUKLEINSÄURE
UND VORRICHTUNG ZUR DURCHFÜHRUNG DES VERFAHRENS
CA2710680C (en) 2007-12-26 2018-10-16 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
WO2009118300A1 (en) 2008-03-25 2009-10-01 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by down-regulating frizzled-4 and/or frizzled-1
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2009148896A2 (en) 2008-05-29 2009-12-10 Nuclea Biotechnologies, LLC Anti-phospho-akt antibodies
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
US9003679B2 (en) * 2008-08-06 2015-04-14 Nike, Inc. Customization of inner sole board
EP3301116A1 (de) 2008-08-25 2018-04-04 Dana Farber Cancer Institute, Inc. Konserviertes influenzahämagglutininepitop und antikörper dagegen
WO2010032060A1 (en) 2008-09-19 2010-03-25 Medimmune Llc Antibodies directed to dll4 and uses thereof
ES2939310T3 (es) 2008-10-27 2023-04-20 Genalyte Inc Biosensores basados en sondeo y detección ópticos
KR20110079693A (ko) 2008-10-29 2011-07-07 와이어쓰 엘엘씨 단일 도메인 항원 결합 분자의 정제 방법
BR122018013284B1 (pt) 2008-10-29 2022-03-03 Ablynx N.V Formulações de moléculas de ligação ao antígeno de domínio único, seu método de formulação e seu uso, kit ou artigo de fabricação, bem como método para preparar uma formulação reconstituída contendo uma molécula de sdab
US8642280B2 (en) 2008-11-07 2014-02-04 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
EP2358392B1 (de) 2008-11-12 2019-01-09 MedImmune, LLC Antikörper-formulierung
JP2012513194A (ja) 2008-12-23 2012-06-14 アストラゼネカ アクチボラグ α５β１に向けられた標的結合剤およびその使用
AU2009334498A1 (en) 2008-12-31 2011-07-21 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
US20110311521A1 (en) 2009-03-06 2011-12-22 Pico Caroni Novel therapy for anxiety
EP2241323A1 (de) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W und Hirnkrebs
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
KR101754433B1 (ko) 2009-05-08 2017-07-05 백시넥스 인코포레이티드 항-ｃｄ100 항체 및 이의 사용 방법
US8568719B2 (en) 2009-08-13 2013-10-29 Crucell Holland B.V. Antibodies against human respiratory syncytial virus (RSV) and methods of use
EP2292266A1 (de) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Behandlung von Krebs durch Modulation von Copine III
US20120244170A1 (en) 2009-09-22 2012-09-27 Rafal Ciosk Treating cancer by modulating mex-3
EP2483289B2 (de) 2009-10-02 2025-03-26 Biogen MA Inc. Verfahren zur vorbeugung und entfernung von trisulphid-bindungen
CA2776385C (en) 2009-10-07 2019-04-09 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
LT2504364T (lt) 2009-11-24 2017-11-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
JP5841072B2 (ja) 2010-02-10 2016-01-06 イミュノジェン・インコーポレーテッド Ｃｄ２０抗体およびその使用
WO2011107586A1 (en) 2010-03-05 2011-09-09 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, Smoc1, tenascin-c and brain cancers
WO2011131611A1 (en) 2010-04-19 2011-10-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
EP2580239A1 (de) 2010-06-10 2013-04-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Behandlung von krebs mittels modulation von mammalian-ste20-like-kinase 3
JP5744196B2 (ja) 2010-07-09 2015-07-08 クルセル ホランド ベー ヴェー 抗ヒト呼吸器多核体ウイルス（ｒｓｖ）抗体および使用の方法
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
JP2013536175A (ja) 2010-07-16 2013-09-19 アブリンクス エン．ヴェー． 修飾された単一ドメイン抗原結合分子及びその使用
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
SG188285A1 (en) 2010-09-02 2013-04-30 Vaccinex Inc Anti-cxcl13 antibodies and methods of using the same
WO2012032143A1 (en) 2010-09-10 2012-03-15 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Phosphorylated twist1 and metastasis
CN103561759B (zh) 2010-10-22 2016-10-12 西雅图遗传学公司 以奥里斯他汀(AURISTATIN)为主的抗体药物结合物与PI3K-AKT mTOR路径抑制剂之间的协同作用
US9921165B2 (en) 2010-11-05 2018-03-20 Genalyte, Inc. Optical analyte detection systems and methods of use
CA2815266C (en) 2010-11-05 2023-09-05 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
WO2012065937A1 (en) 2010-11-15 2012-05-24 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Anti-fungal agents
JP6130350B2 (ja) 2011-03-30 2017-05-17 アブリンクス エン．ヴェー． ＴＮＦαに対する単一ドメイン抗体で免疫障害を処置する方法
CA2833690A1 (en) 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Novel binder-drug conjugates (adcs) and their use
US9562252B2 (en) 2011-05-13 2017-02-07 Biogen Ma Inc. Methods of preventing and removing trisulfide bonds
ES2704038T3 (es) 2011-05-24 2019-03-13 Zyngenia Inc Complejos multiespecíficos multivalentes y monovalentes y sus usos
EP2717911A1 (de) 2011-06-06 2014-04-16 Novartis Forschungsstiftung, Zweigniederlassung Proteintyrosinphosphatase, nicht-rezeptor typ 11 (ptpn11) und dreifach negativer brustkrebs
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
JP2014533247A (ja) 2011-11-01 2014-12-11 バイオノミクス インコーポレイテッド 抗体および癌を治療する方法
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
AU2012332590B2 (en) 2011-11-01 2016-10-20 Bionomics, Inc. Anti-GPR49 antibodies
ES2697674T3 (es) 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
CN109897103B (zh) 2011-11-04 2024-05-17 酵活英属哥伦比亚有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US20140294732A1 (en) 2011-11-08 2014-10-02 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Early diagnostic of neurodegenerative diseases
US20140314787A1 (en) 2011-11-08 2014-10-23 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Treatment for neurodegenerative diseases
JP2015505850A (ja) 2011-12-14 2015-02-26 シアトル ジェネティックス， インコーポレイテッド 新規な抗体薬物コンジュゲート（ａｄｃ）およびそれらの使用
EP2800583A1 (de) 2012-01-02 2014-11-12 Novartis AG Cdcp1 und brustkrebs
AU2013216863B2 (en) 2012-02-10 2018-09-06 Seagen Inc. Detection and treatment of CD30+ cancers
JP6193275B2 (ja) 2012-03-02 2017-09-06 ヴァクシネックス， インコーポレイテッド Ｂ細胞媒介炎症性疾患を治療するための方法
EP3907506A1 (de) 2012-03-12 2021-11-10 The Board of Trustees of the University of Illinois Optische analytdetektionssysteme mit magnetischer verstärkung und verfahren zu deren verwendung
EP2831112A1 (de) 2012-03-29 2015-02-04 Friedrich Miescher Institute for Biomedical Research Hemmung von interleukin 8 und/oder dessen rezeptor cxcrl bei der behandlung von brustkrebs mit her2/her3-überexpression
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
WO2013166594A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
MX362497B (es) 2012-05-15 2019-01-21 Eisai Inc Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.
MX369626B (es) 2012-05-24 2019-11-13 Mountgate Group Ltd Composiciones y metodos relacionados con la prevencion y el tratamiento de infecciones por rabia.
EP2862875B1 (de) 2012-06-14 2023-09-06 Chugai Seiyaku Kabushiki Kaisha Antigenbindendes molekül mit modifizierter fc-region
WO2014001482A1 (en) 2012-06-29 2014-01-03 Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
WO2014006114A1 (en) 2012-07-05 2014-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
WO2014006115A1 (en) 2012-07-06 2014-01-09 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
KR102134088B1 (ko) 2012-08-24 2020-07-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
WO2014122605A1 (en) 2013-02-08 2014-08-14 Friedrich Miescher Institute For Biomedical Research Novel methods for the targeted introduction of viruses into cells
BR112015021964A2 (pt) 2013-03-08 2017-08-29 Vaccinex Inc Anticorpo isolado ou um fragmento ligante de antígenos do mesmo que se liga especificamente a cxcl13, composição e seus usos
WO2014144600A2 (en) 2013-03-15 2014-09-18 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
US9983206B2 (en) 2013-03-15 2018-05-29 The Board Of Trustees Of The University Of Illinois Methods and compositions for enhancing immunoassays
PL3816625T3 (pl) 2013-05-06 2026-01-26 Scholar Rock, Inc. Kompozycje i sposoby modulacji czynnika wzrostu
ES2761587T3 (es) 2013-08-07 2020-05-20 Friedrich Miescher Institute For Biomedical Res Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
US10344319B2 (en) 2013-10-28 2019-07-09 Dots Technology Corp. Allergen detection
US20160280787A1 (en) * 2013-11-11 2016-09-29 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
EP3086814B1 (de) 2013-12-23 2020-06-24 Bayer Pharma Aktiengesellschaft Binder-konjugate (adcs) mit ksp-inhibitoren
KR102352573B1 (ko) 2014-04-04 2022-01-18 바이오노믹스 인코포레이티드 Ｌｇｒ５에 결합하는 인간화된 항체들
RU2689145C2 (ru) 2014-04-16 2019-05-24 Биокон Лтд. Стабильные белковые препараты, содержащие молярный избыток сорбитола
WO2015175874A2 (en) 2014-05-16 2015-11-19 Medimmune, Llc Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
WO2015189816A1 (en) 2014-06-13 2015-12-17 Friedrich Miescher Institute For Biomedical Research New treatment against influenza virus
EP3157535A1 (de) 2014-06-23 2017-04-26 Friedrich Miescher Institute for Biomedical Research Verfahren zur auslösung der novo-bildung von heterochromatin und/oder zur epigenetischen abschaltung mit kleinen rnas
AU2015280436A1 (en) 2014-06-23 2017-02-02 Bionomics, Inc. Antibodies that bind LGR4
EP3164129A1 (de) 2014-07-01 2017-05-10 Friedrich Miescher Institute for Biomedical Research Kombination eines brafv600e-hemmers und mertk-hemmers zur melanombehandlung
US10077309B2 (en) * 2014-07-14 2018-09-18 The Penn State Research Foundation Compositions and methods for targeting of the surfactant protein A receptor
US10961298B2 (en) 2014-08-21 2021-03-30 The Government Of The United States, Represented By The Secretary Of The Army Monoclonal antibodies for treatment of microbial infections
WO2016046768A1 (en) 2014-09-24 2016-03-31 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
JP7125248B2 (ja) 2014-11-11 2022-08-24 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子のライブラリ
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
ES2941897T3 (es) 2014-11-12 2023-05-26 Seagen Inc Compuestos que interaccionan con glicanos y procedimientos de uso
EP3220900B1 (de) 2014-11-21 2020-09-23 University of Maryland, Baltimore Systeme zur gezielten strukturspezifischen partikelabgabe
US10485880B2 (en) 2014-12-15 2019-11-26 Bayer Pharma Aktiengesellschaft Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodies
CA2982400C (en) 2015-03-31 2023-10-24 Medimmune Limited A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
JP6971858B2 (ja) 2015-06-22 2021-11-24 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ）
JP2018528161A (ja) 2015-06-23 2018-09-27 バイエル ファーマ アクチエンゲゼルシャフト Ｋｓｐ阻害剤との部位特異的均一複合体
CN107921145A (zh) 2015-06-23 2018-04-17 拜耳医药股份有限公司 Ksp抑制剂与抗‑tweakr抗体的抗体药物缀合物（adc）
US11071788B2 (en) 2015-06-23 2021-07-27 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies
US11384138B2 (en) 2015-08-19 2022-07-12 Rutgers, The State University Of New Jersey Methods of generating antibodies
HK1258218A1 (zh) 2015-09-15 2019-11-08 Board Of Regents, The University Of Texas System T細胞受體(tcr)結合抗體及其應用
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
US20180348224A1 (en) 2015-10-28 2018-12-06 Friedrich Miescher Institute For Biomedical Resear Ch Tenascin-w and biliary tract cancers
SG11201803213XA (en) 2015-11-12 2018-05-30 Siamab Therapeutics Inc Glycan-interacting compounds and methods of use
AU2017239038B2 (en) 2016-03-22 2024-06-27 Bionomics Inc Administration of an anti-LGR5 monoclonal antibody
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
JP7161266B2 (ja) 2016-08-05 2022-10-26 メディミューン，エルエルシー 抗ｏ２抗体およびその使用
AU2017326751B2 (en) 2016-09-16 2024-10-10 Bionomics Limited Antibody and checkpoint inhibitor combination therapy
AU2017346488A1 (en) 2016-10-19 2019-05-30 Humabs Biomed Sa Anti-O1 antibodies and uses thereof
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
PE20190921A1 (es) 2016-12-07 2019-06-26 Agenus Inc Anticuerpos y metodos de su utilizacion
CA3047491A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
KR102628678B1 (ko) 2016-12-21 2024-01-25 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc)
US11433140B2 (en) 2016-12-21 2022-09-06 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (ADCs) having KSP inhibitors
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
JP7610349B2 (ja) 2017-04-22 2025-01-08 イミュノミック セラピューティックス， インコーポレイテッド 改良ｌａｍｐ構築物
WO2018204534A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
US11655307B2 (en) 2017-05-30 2023-05-23 The Board Of Regents Of The University Of Oklahoma Anti-doublecortin-like kinase 1 antibodies and methods of use
CA3065328C (en) 2017-06-21 2023-08-15 Gilead Sciences, Inc. Multispecific antibodies that target hiv gp120 and cd3
EP3661960A1 (de) 2017-08-04 2020-06-10 Genmab A/S An pd-l1 und cd137 bindende bindemittel und deren verwendung
US20200172933A1 (en) 2017-08-18 2020-06-04 Friedrich Miescher Institute For Biomedical Research Novel methods for the targeted introduction of viruses into cells and tissues
KR20250117487A (ko) 2017-10-11 2025-08-04 씨젠 인크. 항-cd30 항체 약물 콘주게이트 요법의 부작용을 감소시키는 방법
EP3694889A1 (de) 2017-10-13 2020-08-19 Boehringer Ingelheim International GmbH Humane antikörper gegen thomsen-nouvelle (tn)-antigen
MX2020004563A (es) 2017-11-01 2020-08-13 Seattle Genetics Inc Metodos de reduccion de efectos secundarios del tratamiento con conjugado anticuerpo anti-cd30-farmaco.
EP3706795A4 (de) 2017-11-09 2021-10-13 Pinteon Therapeutics Inc. Verfahren und zusammensetzungen zur erzeugung und verwendung von humanisierten konformationsspezifischen phosphorylierten tau-antikörpern
TW201938194A (zh) 2017-12-05 2019-10-01 日商中外製藥股份有限公司 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子
EP3746079A1 (de) 2018-01-31 2020-12-09 Bayer Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) mit nampt-inhibitoren
WO2019178218A1 (en) 2018-03-14 2019-09-19 Memorial Sloan Kettering Cancer Center Anti-polysialic acid antibodies and uses thereof
MX2020009842A (es) 2018-03-23 2020-10-15 Seattle Genetics Inc Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido.
AU2019266205B2 (en) 2018-05-07 2026-01-08 Genmab A/S Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate
BR112020022642A2 (pt) 2018-05-07 2021-02-17 Genmab A/S método para tratar câncer em um indivíduo, e, estojo
US12398195B2 (en) 2018-05-15 2025-08-26 Immunomic Therapeutics, Inc. Lamp constructs comprising allergens
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
US20210275686A1 (en) 2018-06-18 2021-09-09 Bayer Aktiengesellschaft Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile
KR102579246B1 (ko) 2018-07-03 2023-09-19 길리애드 사이언시즈, 인코포레이티드 HIV gp120을 표적화하는 항체 및 사용 방법
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
SG11202101152QA (en) 2018-08-03 2021-03-30 Chugai Pharmaceutical Co Ltd Antigen-binding molecule containing two antigen-binding domains that are linked to each other
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
MX2021003609A (es) 2018-09-28 2021-05-28 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno que comprende una region variable de anticuerpo alterada.
CA3114922A1 (en) 2018-10-01 2020-04-09 Seagen Inc. Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
WO2020163225A1 (en) 2019-02-05 2020-08-13 Seattle Genetics, Inc. Anti-cd228 antibodies and antibody-drug conjugates
US12509515B2 (en) 2019-03-11 2025-12-30 Memorial Sloan Kettering Cancer Center CD22 antibodies and methods of using the same
WO2020198731A2 (en) 2019-03-28 2020-10-01 Danisco Us Inc Engineered antibodies
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
EP4013506A1 (de) 2019-08-12 2022-06-22 Aptevo Research and Development LLC 4-1bb- und ox40-bindende proteine und verwandte zusammensetzungen und verfahren, antikörper gegen 4-1bb, antikörper gegen ox40
MX2022003357A (es) 2019-09-25 2022-05-03 Seagen Inc Combinación de anticuerpo anti-cd30 conjugado con un farmaco, anti-pd-1 y quimioterapia para el tratamiento de cánceres hematopoyéticos.
KR20220075351A (ko) 2019-10-04 2022-06-08 씨젠 인크. 항-pd-l1 항체 및 항체-약물 접합체
WO2021077051A1 (en) 2019-10-18 2021-04-22 Immunomic Therapeutics, Inc Improved lamp constructs comprising cancer antigens
EP4054647A1 (de) 2019-11-04 2022-09-14 Seagen Inc. Anti-cd30-antikörpermedikament-konjugate und ihre verwendung zur behandlung von hiv-infektionen
MX2022005222A (es) 2019-11-07 2022-06-08 Genmab As Metodos para tratar el cancer con una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y un conjugado de anticuerpo anti factor tisular-farmaco.
TW202131954A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
IL295202A (en) 2020-01-31 2022-10-01 Seagen Inc Anti-cd30 antibody-drug conjugates and their use for the treatment of non-Hodgkin's lymphoma
IL296803A (en) 2020-03-31 2022-11-01 Chugai Pharmaceutical Co Ltd Multispecific antigen binding molecules targeting dll3 and their uses
US20230190949A1 (en) 2020-05-13 2023-06-22 Seagen Inc. Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
IL300176A (en) 2020-08-04 2023-03-01 Seagen Inc Anti-CD228 antibodies and antibody-drug conjugates
IL300917A (en) 2020-09-04 2023-04-01 Univ Rutgers Sars-cov-2 vaccines and antibodies
US20230382978A1 (en) 2020-10-15 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
US20240024320A1 (en) 2020-11-17 2024-01-25 Seagen Inc. Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
CA3200314A1 (en) 2020-12-01 2022-06-09 Peter Pavlik Tumor-associated antigens and cd-3 binding proteins, related compositions, and methods
US20240317871A1 (en) 2020-12-30 2024-09-26 Immunomic Therapeutics, Inc. Anti-HVEM Antibodies
TW202245844A (zh) 2021-01-13 2022-12-01 紀念斯隆凱特琳癌症中心 抗dll3抗體-藥物結合物
KR20230146521A (ko) 2021-01-13 2023-10-19 메모리얼 슬로안 케터링 캔서 센터 항체-피롤로벤조디아제핀 유도체 접합체
US20250199013A1 (en) 2021-05-28 2025-06-19 Alexion Pharmaceuticals, Inc. Methods for detecting cm-tma biomarkers
JP2024522213A (ja) 2021-06-14 2024-06-11 アルジェニクス ビーブイ 抗ｉｌ－９抗体及びその使用方法
IL309405A (en) 2021-06-29 2024-02-01 Seagen Inc Methods for treating cancer with a combination of non-fucosylated anti-CD70 antibody and CD47 antagonist
IL309831A (en) 2021-07-13 2024-02-01 BioNTech SE Multispecific binding agents against CD40 and CD137 in combined cancer therapy
US20250002600A1 (en) 2021-10-06 2025-01-02 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination therapy
IL312110A (en) 2021-10-29 2024-06-01 Seagen Inc Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
WO2023192436A1 (en) 2022-03-31 2023-10-05 Alexion Pharmaceuticals, Inc. Singleplex or multiplexed assay for complement markers in fresh biological samples
CA3247515A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructions comprising genes that enhance the immune response and methods of their use
JP2025515166A (ja) 2022-05-06 2025-05-13 ジェンマブ エー／エス 抗組織因子抗体－薬物コンジュゲートを用いたがんの治療方法
JP2025529318A (ja) 2022-09-06 2025-09-04 アレクシオン ファーマシューティカルズ， インコーポレイテッド 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を有する患者における診断及び予後バイオマーカプロファイル
CN120435319A (zh) 2022-11-03 2025-08-05 思进公司 抗-avb6抗体和抗体-药物缀合物及其在癌症治疗中的用途
WO2024105205A1 (en) 2022-11-17 2024-05-23 Bayer Aktiengesellschaft Antibody-drug conjugates (a2dcs) with enzymatically cleavable groups
AU2023379743A1 (en) 2022-11-17 2025-07-03 Sanofi Ceacam5 antibody-drug conjugates and methods of use thereof
CN120302979A (zh) 2022-12-01 2025-07-11 生物技术公司 针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗
JP2026509512A (ja) 2023-03-17 2026-03-19 オキシトープ ファーマ ベー．フェー． 抗ホスホコリン抗体およびその使用方法
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
EP4688160A1 (de) 2023-04-06 2026-02-11 Genmab A/S Multispezifische bindemittel gegen pd-l1 und cd137 zur behandlung von krebs
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
US20250109187A1 (en) 2023-09-28 2025-04-03 Novavax, Inc. ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025155971A1 (en) 2024-01-19 2025-07-24 Immunomic Therapeutics, Inc Anti-activin receptor 1c (alk-7) receptor antibodies
TW202545567A (zh) 2024-01-30 2025-12-01 美商思進公司 抗ｐｄ－ｌ１抗體和抗體－藥物共軛體及彼等在治療癌症的用途
US20250295801A1 (en) 2024-03-21 2025-09-25 Seagen Inc. Cd25 antibodies, antibody drug conjugates, and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983003679A1 (en) * 1982-04-12 1983-10-27 Hybritech Inc Antibodies having dual specificities, their preparation and uses therefor
EP0361908A2 (de) * 1988-09-28 1990-04-04 Ideon Corporation Immunotherapeutische Kombination von Enzymen
EP0363712A2 (de) * 1988-09-27 1990-04-18 Takeda Chemical Industries, Ltd. Hybride monoklonale Antikörper, ihre Herstellung und Verwendung
WO1990007714A1 (en) * 1988-12-23 1990-07-12 Applied Research Systems Ars Holding N.V. Homogeneous encym immunoassay

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401764A (en) * 1980-02-07 1983-08-30 Technicon Instruments Corporation Immunoassays employing labeled reagent and a conjugate having two binding sites
CA1194415A (en) * 1982-05-05 1985-10-01 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4446233A (en) * 1982-05-05 1984-05-01 E. I. Du Pont De Nemours And Company Homogeneous immunoassay using covalent hybrid antibodies
IT1199088B (it) * 1984-03-09 1988-12-30 Miles Italiana Saggio di legame specifico mediante impiego di anti-g6pdh come marcante
EP0329184A3 (de) * 1988-02-19 1990-05-23 Neorx Corporation Antimere und antimere Konjugation
AU6290090A (en) * 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
WO1991009134A1 (en) * 1989-12-15 1991-06-27 Takeda Chemical Industries, Ltd. Biospecific antibody to cancer cell and enzyme with prodrug-activating characteristics
CA2075927A1 (en) * 1990-02-16 1991-08-17 Victor A. Raso Hybrid reagents capable of selectively releasing molecules into cells
US5273743A (en) * 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983003679A1 (en) * 1982-04-12 1983-10-27 Hybritech Inc Antibodies having dual specificities, their preparation and uses therefor
EP0363712A2 (de) * 1988-09-27 1990-04-18 Takeda Chemical Industries, Ltd. Hybride monoklonale Antikörper, ihre Herstellung und Verwendung
EP0361908A2 (de) * 1988-09-28 1990-04-04 Ideon Corporation Immunotherapeutische Kombination von Enzymen
WO1990007714A1 (en) * 1988-12-23 1990-07-12 Applied Research Systems Ars Holding N.V. Homogeneous encym immunoassay

Also Published As

Publication number Publication date
DK0511011T3 (da) 1997-03-10
GR3022065T3 (en) 1997-03-31
US5573920A (en) 1996-11-12
ES2093778T3 (es) 1997-01-01
IE921342A1 (en) 1992-11-04
AU665758B2 (en) 1996-01-18
CN1047666C (zh) 1999-12-22
ATE144624T1 (de) 1996-11-15
HU9303026D0 (en) 1994-01-28
DE69214709T2 (de) 1997-02-20
CA2108451A1 (en) 1992-10-27
DE69214709D1 (de) 1996-11-28
IL101690A (en) 1996-12-05
IL101690A0 (en) 1992-12-30
EP0582595A1 (de) 1994-02-16
HUT66753A (en) 1994-12-28
EP0511011A1 (de) 1992-10-28
CN1069124A (zh) 1993-02-17
AU1661892A (en) 1992-12-21
NZ242510A (en) 1994-08-26
US5855886A (en) 1999-01-05
JP3431140B2 (ja) 2003-07-28
EP0511011B1 (de) 1996-10-23
AP9200376A0 (en) 1992-04-30
WO1992019973A1 (en) 1992-11-12
JPH06506827A (ja) 1994-08-04

Similar Documents

Publication Publication Date Title
AP257A (en) A method of releasing an antigen from an antibody and methods for their use in diagnosis and therapy.
JPH02500004A (ja) 非還元・非酵素的糖鎖形成蛋白に対するモノクローナル抗体
JP2988635B2 (ja) ヒトＩｇＥに対するモノクローナル抗体
JPS62246596A (ja) 改質β↓２マイクログロブリン
JP3345507B2 (ja) アシアログリコプロテインレセプターの測定法及びこれに用いる測定試薬
JPH07304800A (ja) ヒトペプシノゲンに対するモノクローナル抗体
JPH01500564A (ja) ヒトリンホサイトＩｇＥレセプターに対するモノクロナール抗体、該抗体を産生するハイブリドーマ及び該抗体を用いるキット
JP2518602B2 (ja) ヒトプロテインｓに対するモノクロ―ナル抗体を用いた免疫学的測定試薬及びキット
JP3036545B2 (ja) モノクローナル抗体とこれを産生するハイブリドーマ細胞株、およびこれを用いる免疫学的測定法
JPS61286753A (ja) モノクロ−ナル抗体を用いた免疫学的測定方法およびそのためのキツト
CN118652346A (zh) 靶向幽门螺旋杆菌b型尿素酶的抗体及其应用
JPS62135770A (ja) ヒトインタ−ロイキン−２の測定法，測定用試薬，抗体および複合体
Rudenko et al. Production and characterization of the monoclonal antibodies to Bacillus anthracis protective antigen
JPS59226864A (ja) トランスホ−ミンググロスファクタ−の酵素免疫測定法
JPS61213671A (ja) ヒトプラスミン−α↓２−プラスミンインヒビタ−複合体の測定法
CN120248118A (zh) 一种识别白介素8的抗体及其应用
WO2014168242A1 (ja) 歯周病特異的ペプチドに対するモノクローナル抗体およびその用途
JPH04325095A (ja) 抗ヒトｉｌ−６モノクロ−ナル抗体及び該抗体を使用するｉｌ−６の測定方法
JPS62180270A (ja) インタ−フエロン−γの免疫化学的測定法および測定用試薬
JPH01232264A (ja) 酵素免疫学的測定方法に基づくヒト血漿中のヒトプロテインｓの定量法
JPH01131462A (ja) 慢性関節リウマチ疾患の診断法
ANFOSSO et al. 1.1 Efficiency of human IgE IRMA is dependent of monoclonal antibody fine specificity and solid-phase nature
JPH03127997A (ja) ヒト１ｇＥ結合因子に特異的なモノクローン抗体、それを産生するハイブリドーマおよびその用途
JPS6197230A (ja) ヒトα↓２―プラスミンインヒビターに対する選択的吸着体
JPH0355106B2 (de)